EP2334302B1 - Dosage forms for weakly ionizable compounds - Google Patents

Dosage forms for weakly ionizable compounds

Info

Publication number: EP2334302B1
Authority: EP; European Patent Office
Prior art keywords: dosage forms; ionizable compounds; weakly ionizable; weakly; compounds
Prior art date: 2008-09-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn - After Issue

Application number

EP09792369.2A

Other languages

German (de)

French (fr)

Other versions

EP2334302A2 (en

Inventor

Vikas Agarwal

Sami M Nazzal

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Cima Labs Inc

Original Assignee

Cima Labs Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-09-09

Filing date

2009-09-09

Publication date

2018-03-21

2009-09-09 Application filed by Cima Labs Inc filed Critical Cima Labs Inc

2011-06-22 Publication of EP2334302A2 publication Critical patent/EP2334302A2/en

2018-03-21 Application granted granted Critical

2018-03-21 Publication of EP2334302B1 publication Critical patent/EP2334302B1/en

Status Withdrawn - After Issue legal-status Critical Current

2029-09-09 Anticipated expiration legal-status Critical

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

EP09792369.2A 2008-09-09 2009-09-09 Dosage forms for weakly ionizable compounds Withdrawn - After Issue EP2334302B1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US9549308P	2008-09-09	2008-09-09
US16199209P	2009-03-20	2009-03-20
PCT/US2009/056362 WO2010030667A2 (en)	2008-09-09	2009-09-09	Dosage forms for weakly ionizable compounds

Publications (2)

Publication Number	Publication Date
EP2334302A2 EP2334302A2 (en)	2011-06-22
EP2334302B1 true EP2334302B1 (en)	2018-03-21

Family

ID=41667166

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP09792369.2A Withdrawn - After Issue EP2334302B1 (en)	2008-09-09	2009-09-09	Dosage forms for weakly ionizable compounds

Country Status (5)

Country	Link
EP (1)	EP2334302B1 (en)
JP (1)	JP5661630B2 (en)
CA (1)	CA2735660C (en)
MX (1)	MX340669B (en)
WO (1)	WO2010030667A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN105431145B (en)	2013-04-05	2019-12-10	Sc医药品有限公司	Pharmaceutical formulation for subcutaneous administration of furosemide
CN108295264A (en) *	2018-03-28	2018-07-20	五邑大学	The application of polyvinylpyrrolidone k12
WO2020120482A1 (en)	2018-12-10	2020-06-18	Sq Innovation Ag	Pharmaceutical compositions of furosemide and uses thereof
CN113271923B (en)	2019-01-04	2025-05-13	Sq创新股份公司	Furosemide pharmaceutical composition and use thereof
EP3906020B1 (en)	2019-01-04	2025-12-31	SQ Innovation AG	Pharmaceutical compositions of torsemide and uses thereof
CA3128033A1 (en)	2019-01-31	2020-08-06	Scpharmaceuticals Inc.	Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6613332B1 (en) *	1991-06-21	2003-09-02	The University Of Cincinnati	Oral administration of therapeutic proteins
US6350470B1 (en) *	1998-04-29	2002-02-26	Cima Labs Inc.	Effervescent drug delivery system for oral administration
EP1104290B1 (en) *	1998-08-13	2010-03-31	Cima Labs Inc.	Microemulsions as solid dosage forms for oral administration
US6228400B1 (en) *	1999-09-28	2001-05-08	Carlsbad Technology, Inc.	Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
AU1548001A (en) *	1999-11-24	2001-06-04	Wakamoto Pharmaceutical Co., Ltd.	Ophthalmic aqueous preparation
JP5684440B2 (en) *	2001-02-23	2015-03-11	シーマ・ラブス、インコーポレイテッド	Compositions and solid formulations
DE102004021281A1 (en) *	2004-04-29	2005-11-24	Boehringer Ingelheim Vetmedica Gmbh	Use of meloxicam formulations in veterinary medicine

2009
- 2009-09-09 MX MX2011002084A patent/MX340669B/en active IP Right Grant
- 2009-09-09 JP JP2011526303A patent/JP5661630B2/en not_active Expired - Fee Related
- 2009-09-09 EP EP09792369.2A patent/EP2334302B1/en not_active Withdrawn - After Issue
- 2009-09-09 CA CA2735660A patent/CA2735660C/en not_active Expired - Fee Related
- 2009-09-09 WO PCT/US2009/056362 patent/WO2010030667A2/en not_active Ceased

Also Published As

Publication number	Publication date
MX340669B (en)	2016-07-20
JP2012502065A (en)	2012-01-26
JP5661630B2 (en)	2015-01-28
EP2334302A2 (en)	2011-06-22
CA2735660A1 (en)	2010-03-18
WO2010030667A3 (en)	2010-07-22
MX2011002084A (en)	2011-03-29
CA2735660C (en)	2017-05-30
WO2010030667A2 (en)	2010-03-18

Publication	Publication Date	Title
ZA201104336B (en)	2016-10-26	Pharmaceutical compounds
GB0816372D0 (en)	2008-10-15	Pharmaceutical compounds
GB0820819D0 (en)	2008-12-24	Pharmaceutical compounds
GB0801416D0 (en)	2008-03-05	Pharmaceutical compounds
IL207128A0 (en)	2010-12-30	Pharmaceutical dosage form
IL209895A0 (en)	2011-02-28	Compounds for treating beta-amyloidoses
GB0816371D0 (en)	2008-10-15	Pharmaceutical compounds
IL200020A0 (en)	2010-04-15	Dosage regimen for comt inhibitors
GB0813740D0 (en)	2008-09-03	Therapeutic compounds
GB0806794D0 (en)	2008-05-14	Therapeutic compounds
GB0804755D0 (en)	2008-04-16	Therapeutic compounds
GB0812969D0 (en)	2008-08-20	Pharmaceutical compounds
ZA200903858B (en)	2013-10-30	Pharmaceutical dosage form
PL2271618T3 (en)	2014-09-30	Pharmaceutical compounds
GB0816370D0 (en)	2008-10-15	Pharmaceutical compounds
GB0810857D0 (en)	2008-07-23	Pharmaceutical compounds
EP2285385A4 (en)	2013-01-16	siRNA COMPOUNDS FOR INHIBITING NRF2
EP2334302B1 (en)	2018-03-21	Dosage forms for weakly ionizable compounds
EP2265260A4 (en)	2013-07-03	Solid dosage form for treating headaches
ZA201100163B (en)	2011-09-28	Unit dosage of apadenoson
PL2519233T3 (en)	2015-06-30	Pharmaceutical composition for treating alcohol dependency
GB0908905D0 (en)	2009-07-01	Pharmaceutical compounds
HK1158980A (en)	2012-07-27	Dosage forms for weakly ionizable compounds
EP2276769A4 (en)	2011-08-17	New peptidomimetic compounds
GB0802576D0 (en)	2008-03-19	Dosage form

Legal Events

Date	Code	Title	Description
2011-05-20	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2011-06-22	17P	Request for examination filed	Effective date: 20110411
2011-06-22	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
2011-06-22	AX	Request for extension of the european patent	Extension state: AL BA RS
2012-07-27	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1158980 Country of ref document: HK
2016-11-09	17Q	First examination report despatched	Effective date: 20161007
2017-10-10	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2017-11-08	INTG	Intention to grant announced	Effective date: 20171011
2018-02-12	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2018-02-16	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2018-03-02	PUAC	Information related to the publication of a b1 document modified or deleted	Free format text: ORIGINAL CODE: 0009299EPPU
2018-03-09	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN
2018-03-21	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
2018-03-21	AX	Request for extension of the european patent	Extension state: AL BA RS
2018-03-21	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2018-03-29	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP Ref country code: CH Ref legal event code: PK Free format text: DIE ERTEILUNG WURDE VOM EPA WIDERRUFEN.
2018-04-04	DB1	B1 document deleted	Effective date: 20180302
2018-04-11	18W	Application withdrawn	Effective date: 20180222
2018-04-11	REG	Reference to a national code	Ref country code: LU Ref legal event code: HK Effective date: 20180328
2018-04-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 980352 Country of ref document: AT Kind code of ref document: T Effective date: 20180415
2018-04-18	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2018-04-19	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602009051381 Country of ref document: DE
2018-05-09	REG	Reference to a national code	Ref country code: DE Ref legal event code: R107 Ref document number: 602009051381 Country of ref document: DE
2018-05-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REZ Ref document number: 980352 Country of ref document: AT Kind code of ref document: T Effective date: 20180321
2019-03-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: PK Free format text: DAS LOESCHDATUM WURDE ERGAENZT / LE CHAMP DATE DE RADIATION A ETE COMPLETE / LA DATA DI CANCELLAZIONE E STATA COMPLETATA